Drug Origin Transparency Act of 2023

Bill 118 HR 3810, also known as the Drug Origin Transparency Act of 2023, aims to increase transparency in the pharmaceutical industry by requiring drug manufacturers to disclose the origin of their products. The bill specifically targets drugs that are imported from foreign countries, requiring manufacturers to provide detailed information on where the drug was produced, processed, and packaged.

The legislation also mandates that drug manufacturers disclose any financial relationships they have with foreign entities involved in the production of the drug. This information is intended to help consumers make more informed decisions about the safety and quality of the medications they are taking.

Additionally, the Drug Origin Transparency Act of 2023 includes provisions to strengthen the oversight of drug imports, including increased inspections of foreign manufacturing facilities and stricter penalties for companies that fail to comply with the disclosure requirements. Overall, the bill seeks to improve transparency and accountability in the pharmaceutical industry, ultimately aiming to ensure the safety and efficacy of drugs imported into the United States.